Tuberculosis Treatment Monitoring
Tuberculosis
ResearchActive
Key Facts
About The eNose Company
The eNose Company is pioneering breath analysis for medical diagnostics using its proprietary electronic nose technology. It has advanced its lead program for detecting lung cancer and COVID-19 into clinical validation and commercialization phases, with a broader pipeline targeting asthma, COPD, and other conditions. As a publicly traded company on Euronext Access Paris, it operates in a high-growth digital diagnostics market but faces risks related to clinical validation, reimbursement, and competition from established diagnostic methods and emerging AI-driven platforms.
View full company profileTherapeutic Areas
Other Tuberculosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Isoniazid Oral Solution, USP | CMP Pharma | Approved |
| Tuberculosis Program | Fimbrion Therapeutics | Preclinical |
| Undisclosed Program | Crestone | Preclinical |
| Tuberculosis Diagnostic | GenEndeavor | Research/Exploratory |
| TB Screening LFA | DiagMetrics | Development |
| RGFields for Tuberculosis | Anapole Technologies | Pre-clinical |
| Tuberculosis Nanobody | VicuTec Biologicals | Pre-clinical |
| ALF Platform | Senzo | Pre-clinical |
| Satiro Tablets | KYORIN Pharmaceutical | Registration |